Friday, March 24, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Assessing the Effectiveness of TB Diagnostics

by Global Biodefense Staff
September 29, 2014
Deadly Tuberculosis in Lungs

Experts at the Liverpool School of Tropical Medicine (LSTM) have used a novel modelling approach to project the effects of new diagnostic methods and algorithms for the diagnosis of TB recently endorsed by the WHO.

Experts at LSTM have used a novel modelling approach to project the effects of new diagnostic methods and algorithms for the diagnosis of tuberculosis (TB) recently endorsed by the World Health Organization (WHO), looking at the patient, health system and population perspective in Tanzania.

In a paper published in the journal The Lancet Global Health, LSTM’s Ivor Langley and Professor Bertie Squire worked with colleagues from the Institute of Epidemiology and Preventative Medicine, National Taiwan University; National Tuberculosis and Leprosy Programme, Tanzania; Department of Epidemiology, Harvard School of Public Health and Brigham and Women’s hospital, Boston, MA., using an integrated model to assess the effects of a number different algorithms in order to assist national TB programmes who now face a decision about which methods to implement.

The model was designed to represent the operational and epidemiological context of Tanzania and was used to compare the effects and cost-effectiveness of different diagnostic options.

At its heart, the study projected, over a 10 year time frame, three parameters which are critical in health policy decision-making: cost per additional disability-adjusted life-years (DALYs) averted, total DALYs averted, and total health budget. The modelling permitted projection of all three of these parameters for a number of different diagnostic algorithms. The team identified three algorithms as cost-effective in Tanzania, where in 2011 the incidence of TB was 169 per 100,000 with 38% of patients co-infected with HIV.

The algorithm with the greatest cost-effectiveness deployed Xpert MTB/RIF for all presumed TB cases. This is a cartridge based automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) with improved accuracy as well as detect resistance to rifampicin (RIF). Although this algorithm was also below Tanzania’s willingness to pay threshold of USD 599 (GDP per head) per DALY, it would cost USD 36 million to implement.

This would require Tanzania to mobilize a 25% increase in its total budget for TB control. The next most cost effective algorithm deployed same-day LED fluorescence microscopy for all presumed TB cases. Although the population level effect was less than Xpert MTB/RIF, the additional cost to the health system was only USD 5.7 million; arguably a more affordable option.

Professor Bertie Squire, Senior Author said: “A key feature of our modelling approach is that it takes into account the knock-on effects of introducing a new diagnostic test on the whole diagnostic process in a given context. This is a more useful way of assessing the potential impact of new diagnostics over conventional assessments such as those focusing largely on test accuracy. Our results provide a wish list for policy makers when deciding to deploy new diagnostics in a country, and the model not only predicts that a full roll-out of Xpert is a cost-effective option with the potential to substantially reduce the national burden of TB, but estimates the substantial level of funding that will need to be mobilized to translate this into clinical practice. Although we focused only on Tanzania in the present analysis, our key findings on the rank of alternative diagnostic options should be generalizable to countries of similar operational and epidemiological situations.”

The research was supported through TREAT TB – a USAID-funded research initiative led by the International Union against Tuberculosis and Lung Disease (The Union).

Read more at The Lancet Global Health: Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa.

Tags: Tuberculosis

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Bat Virus Receptor Studies Vital to Predict Spillover Risk
Pathogens

Bat Virus Receptor Studies Vital to Predict Spillover Risk

December 7, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy